Singapore, July 3 -- AN Venture Partners (ANV), a global biotech venture capital firm, has announced the final close of its first fund, AN Venture Partners I, LP, achieving its target of $200 million (JPY29 billion), one of the largest Japan-focused biotech venture capital funds to date, and also one of the largest first-time biotech venture capital funds raised in the past year.

More than 20 Limited Partners (LPs) have invested in the fund, led by Japan Investment Corporation, Shionogi & Co., Otsuka Pharmaceutical Co., MUFG Bank,. and Sumitomo Mitsui Banking Corporation.

ANV will invest across all stages, from pre-proof-of-concept to advanced clinical stages, and sources, whether academia, big pharma spin-outs or combinations thereof, ...